Exabis Library
Welcome to the e-CCO Library!
P640: Serologic response and safety after third dose of the COVID-19 BNT162b2 vaccine in patients with Inflammatory Bowel Diseases
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P640: Serum ustekinumab levels achieved with a subcutaneous induction regimen correlate to clinical outcome – a prospective study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P641 An increased baseline mucosal TNF burden linked to adalimumab non-response: opportunities for therapeutic drug monitoring
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P641: Bowel Doppler Signal, the most important ultrasonographic feature in clinical practice in managing Inflammatory Bowel Diseases patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P641: Comparison of rectal and oral mesalazine for treatment of rectal ulcerative proctitis: A prospective randomised clinical trial (CORRECT study)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P641: Impact of lockdown period due to COVID-19 pandemic in patients with Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P641: Implementation and short-term adverse events of anti-SARS-CoV-2 vaccines in Inflammatory Bowel Disease patients: an international web-based survey
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P641: Long-term outcome of adalimumab therapy and predictors of response in 254 patients with Crohn's disease: a hospital-based cohort study from Korea
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P641: Ustekinumab efficiency as a higher-line therapy in association with serum levels in patients with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P642 Serum adalimumab levels measured between days 9 and 13 from drug injection can be interpreted clinically in a similar way to trough levels in patients with inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P642: Adaptive dosing during infliximab induction therapy can improve mucosal healing rates in patients with ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P642: Anxiety and depression: beyond simple consequences of chronic inflammatory bowel diseases
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P642: Crossroads of vitamin B6 deficiency and inflammation in inflammatory bowel disease: Preliminary results of a cross-sectional study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P642: Effects of Covid-19 on employment in IBD patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P642: Impact of histological and endoscopic remission in clinical recurrence and recurrence-free time in ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P642: Network meta-analysis: efficacy and safety of treatments for fistulising Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P643 Development of quantitative ultrasonographic activity score in ileal Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P643: Effectiveness of enhanced recovery after surgery in IBD: a propensity score matched cohort study in a single Italian centre
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P643: Filgotinib decreases systemic and mucosal markers of inflammation that are associated with endoscopic improvement in moderately to severely active Crohn’s disease patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P643: Generalizability of Crohn’s disease randomized controlled trials compared to clinical practice
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM